Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Neurochem ; 109(1): 25-34, 2009 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19183256

RESUMO

Lithium is used for several decades to treat manic-depressive illness (bipolar affective disorder). Recently, it was found that lithium induces autophagy, thereby promoting the clearance of mutant huntingtin and alpha-synucleins in experimental systems. We show here for the first time that lithium significantly reduces the amount of pathological prion protein (PrP(Sc)) in prion-infected neuronal and non-neuronal cultured cells by inducing autophagy. Treatment of prion-infected cells with 3-methyladenine, a potent inhibitor of autophagy, counteracted the anti-prion effect of lithium, demonstrating that induction of autophagy mediates degradation of PrP(Sc). Co-treatment with lithium and rapamycin, a drug widely used to induce autophagy, had an additive effect on PrP(Sc) clearance compared to treatment with either drug alone. In addition, we provide evidence that the ability to reduce PrP(Sc) and to induce autophagy is common for diverse lithium compounds, not only for the drug lithium chloride, usually administered in clinical therapy. Furthermore, we show here that besides reduction of PrP(Sc)-aggregates, lithium-induced autophagy also slightly reduces the levels of cellular prion protein. Limiting the substrate available for conversion of cellular prion protein into PrP(Sc) may provide an additional mechanism for reduction of PrP(Sc) by lithium-induced autophagy.


Assuntos
Autofagia/efeitos dos fármacos , Compostos de Lítio/farmacocinética , Proteínas PrPSc/metabolismo , Doenças Priônicas/tratamento farmacológico , Doenças Priônicas/metabolismo , Animais , Autofagia/fisiologia , Linhagem Celular Tumoral , Células Cultivadas , Compostos de Lítio/uso terapêutico , Taxa de Depuração Metabólica/efeitos dos fármacos , Taxa de Depuração Metabólica/fisiologia , Camundongos
2.
J Neurochem ; 107(1): 218-29, 2008 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-18691383

RESUMO

A hallmark in prion diseases is the conformational transition of the cellular prion protein (PrP(C)) into a pathogenic conformation, designated scrapie prion protein (PrP(Sc)), which is the essential constituent of infectious prions. Here, we show that epigallocatechin gallate (EGCG) and gallocatechin gallate, the main polyphenols in green tea, induce the transition of mature PrP(C) into a detergent-insoluble conformation distinct from PrP(Sc). The PrP conformer induced by EGCG was rapidly internalized from the plasma membrane and degraded in lysosomal compartments. Isothermal titration calorimetry studies revealed that EGCG directly interacts with PrP leading to the destabilizing of the native conformation and the formation of random coil structures. This activity was dependent on the gallate side chain and the three hydroxyl groups of the trihydroxyphenyl side chain. In scrapie-infected cells EGCG treatment was beneficial; formation of PrP(Sc) ceased. However, in uninfected cells EGCG interfered with the stress-protective activity of PrP(C). As a consequence, EGCG-treated cells showed enhanced vulnerability to stress conditions. Our study emphasizes the important role of PrP(C) to protect cells from stress and indicate efficient intracellular pathways to degrade non-native conformations of PrP(C).


Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Flavonoides/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Fenóis/farmacologia , Proteínas PrPC/efeitos dos fármacos , Proteínas PrPSc/antagonistas & inibidores , Doenças Priônicas/tratamento farmacológico , Animais , Antioxidantes/metabolismo , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Catequina/análogos & derivados , Catequina/metabolismo , Catequina/farmacologia , Catequina/uso terapêutico , Morte Celular/efeitos dos fármacos , Morte Celular/fisiologia , Linhagem Celular Tumoral , Medicamentos de Ervas Chinesas/metabolismo , Medicamentos de Ervas Chinesas/uso terapêutico , Endocitose/efeitos dos fármacos , Endocitose/fisiologia , Flavonoides/metabolismo , Flavonoides/uso terapêutico , Humanos , Lisossomos/efeitos dos fármacos , Lisossomos/metabolismo , Camundongos , Estrutura Molecular , Estresse Oxidativo/fisiologia , Fenóis/metabolismo , Fenóis/uso terapêutico , Polifenóis , Proteínas PrPC/metabolismo , Proteínas PrPSc/biossíntese , Doenças Priônicas/metabolismo , Doenças Priônicas/fisiopatologia , Conformação Proteica/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Solubilidade
3.
EMBO Rep ; 5(5): 527-31, 2004 May.
Artigo em Inglês | MEDLINE | ID: mdl-15071493

RESUMO

The inhibition of CD40-CD40L interaction-mediated signalling was suggested as a therapeutic strategy for the treatment of Alzheimer's disease. Conversely, CD40-deficient neurons were reported to be more vulnerable to stress associated with ageing as well as nerve growth factor-beta and serum withdrawal. We studied the scrapie infection of CD40L-deficient (CD40L(-/-)) mice to see whether ablation of the CD40L gene would be beneficial or detrimental in this model of a neurodegenerative amyloidosis. CD40L(-/-) mice died on average 40 days earlier than wild-type control mice and exhibited a more pronounced vacuolation of the neuropil and an increased microglia activation. The experimental model indicates that a deficiency for CD40L is highly detrimental in prion diseases and reinforces the neuroprotective function of intact CD40-CD40L interactions. The stimulation of neuroprotective pathways may represent a possibility to delay therapeutically the disease onset in prion infections of the central nervous system.


Assuntos
Ligante de CD40/metabolismo , Neurônios , Scrapie , Doença de Alzheimer/fisiopatologia , Animais , Biomarcadores , Encéfalo/citologia , Encéfalo/metabolismo , Encéfalo/patologia , Antígenos CD40/metabolismo , Ligante de CD40/genética , Progressão da Doença , Feminino , Humanos , Camundongos , Camundongos Endogâmicos , Camundongos Knockout , Neurônios/citologia , Neurônios/metabolismo , Neurônios/patologia , Príons/metabolismo , Scrapie/genética , Scrapie/metabolismo , Scrapie/patologia , Transdução de Sinais/fisiologia , Taxa de Sobrevida , Ácido gama-Aminobutírico/metabolismo
4.
Neurodegener Dis ; 1(6): 266-8, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-16908977

RESUMO

Fyn is a 59-kDa member of the Src family of tyrosine kinases synthesized on cytosolic polysomes and then targeted to the plasma membrane where it clusters in caveolae-like membrane microdomains. The cellular isoform of the prion protein (PrP) has also been identified to be a caveolar constituent and to participate in signal transduction events concerning cell survival and differentiation via recruitment of Fyn. We studied the scrapie infection of mice deficient for Fyn (Fyn(-/-)) to clarify the role of Fyn in an in vivo model of transmissible spongiforme encephalopathies. Fyn(-/-) mice died on average 9 days earlier than wild-type control mice, but no differences were seen regarding activation of astrocytes, vacuolization of the neuropil, and accumulation of misfolded prion protein. The experimental model suggests that a deficiency for Fyn is detrimental in prion diseases, although it has no major effect on the clinical course of an experimental prion infection of the CNS.


Assuntos
Encéfalo/enzimologia , Predisposição Genética para Doença/genética , Proteínas PrPSc/metabolismo , Proteínas Proto-Oncogênicas c-fyn/genética , Scrapie/enzimologia , Scrapie/genética , Animais , Biomarcadores/metabolismo , Encéfalo/patologia , Feminino , Proteína Glial Fibrilar Ácida/metabolismo , Gliose/genética , Gliose/metabolismo , Gliose/patologia , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Neurópilo/enzimologia , Neurópilo/patologia , Scrapie/patologia
5.
Neurosci Lett ; 350(3): 187-9, 2003 Oct 30.
Artigo em Inglês | MEDLINE | ID: mdl-14550926

RESUMO

Several lines of evidence suggest that immunisations may be helpful in the prophylaxis and treatment of neurodegenerative amyloidoses like Alzheimer's disease and prion infections. We used a synthetic prion protein-derived peptide (PrP105-125) and a recombinant PrP fragment (PrP90-230) as antigens for the active immunisation of mice, which were subsequently infected by dietary exposure to the scrapie agent. Immunisation with PrP105-125 prolonged the survival times significantly. In contrast, immunisation with PrP90-230 or adjuvants alone had no effect on the disease development. An epitope mapping of the antibodies raised against PrP90-230 revealed that reactivities against previously defined protective epitopes were either underrepresented or absent. These results point towards the possibility to prevent prion spread via the food chain by vaccinating humans or other species at risk to contract prion diseases.


Assuntos
Príons/imunologia , Príons/uso terapêutico , Scrapie/imunologia , Scrapie/prevenção & controle , Vacinação , Administração Oral , Animais , Anticorpos/sangue , Ensaio de Imunoadsorção Enzimática , Camundongos , Peptídeos , Proteínas PrPSc/administração & dosagem , Proteínas Recombinantes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA